Spectrum Pharmaceuticals has received a consensus rating of Buy.
Is SPB a buy?
may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of SPB, demonstrate its potential to outperform the market. It currently has a Growth Score of B.
Why is Spectrum Pharmaceuticals stock dropping?
Why Spectrum Pharmaceuticals Stock Is Crashing Today The big decline came after the company announced that the U.S. Food and Drug Administration turned down approval of Rolontis in treating neutropenia in patients receiving cancer drugs that decrease bone marrow activity.4 days ago
Did Sppi get FDA approval?
--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of Beleodaq™ for the
Is Rolontis FDA approved?
ROLONTIS® (eflapegrastim) is an investigational drug not approved by the FDA. ROLONTIS® (eflapegrastim) is an investigational granulocyte-colony stimulating factor (G-CSF) analog. It comprises two protein components—an analog of G-CSF and an Fc antibody fragment—tethered by a flexible polyethylene-glycol linker. >
Can you buy Spectrum stock?
Latest market close $87.13
----------------------------------------- -------------
Wall St. target price $125.14
PE ratio more info button 20.278
Dividend yield more info button $1.68 (1.88%)
Earnings per share (TTM) more info button $4.39
Is Spectrum Brands a good stock to buy?
Spectrum Brands has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Should I buy stock in Spectrum Pharmaceuticals?
There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Spectrum Pharmaceuticals stock.